Table 3. Top 10 adverse events.
| Cytotoxic Combination Trials (N=67) | Molecularly Targeted Single Agent Trials (N=60) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 | n (%) | Cycles 2-6 | n (%) | Cycle 1 | n (%) | Cycles 2-6 | n (%) |
| Diarrhoea | 36 (53.7) | Fatigue | 24 (35.8) | Fatigue | 25 (41.7) | Fatigue | 20 (33.3) |
| Rasha | 32 (47.8) | Diarrhoea | 19 (28.4) | Diarrhoea | 19 (31.7) | Anorexia | 12 (20.0) |
| Fatigue | 28 (41.8) | Mucositisb | 18 (26.9) | Nausea | 18 (30.0) | Diarrhoea | 10 (16.7) |
| Mucositisb | 23 (34.3) | Alopecia | 14 (20.9) | Rasha | 14 (23.3) | Rasha | 9 (15.0) |
| Nausea | 22 (32.8) | Rasha | 12 (17.9) | Mucositisb | 9 (15.0) | Vomiting | 9 (15.0) |
| Pyrexia | 16 (23.9) | Vomiting | 12 (17.9) | Anorexia | 8 (13.3) | Nausea | 9 (15.0) |
| Anorexia | 11 (16.4) | Nausea | 10 (14.9) | Dysgeusia | 6 (10.0) | Oedema | 6 (10.0) |
| Constipation | 9 (13.4) | Anorexia | 10 (14.9) | Urine Discoloration | 5 (8.3) | Increased Bilirubin | 5 (8.3) |
| Epistaxis | 8 (11.9) | Anaemia | 9 (13.4) | Dry Skin | 5 (8.3) | Mucositisb | 5 (8.3) |
| Neutropeniac | 8 (11.9) | Neutropeniac | 8 (11.9) | Dyspepsia | 5 (8.3) | Pain | 5 (8.3) |
Ranked adverse events by trial type and cycle number, either cycle 1 or cycles 2-6. AEs were ranked to show top 10 in each trial and cycle group. AEs are displayed in ascending order of raw count with percentage incidence given in brackets.
a including pruritic, fungal, macropapular, acneiform, pustular.
b including stomatitis and coryzal symptoms.
c including resultant fever or sepsis.